Real‐world results with IgPro20 for hypo‐ or agammaglobulinemia in Japan

Background Subcutaneous immunoglobulin is one of the standard treatments for hypogammaglobulinemia in primary immunodeficiencies (PID) worldwide. In Japan, IgPro20 (Hizentra®; l‐proline‐stabilized 20% human subcutaneous immunoglobulin) is approved for agammaglobulinemia or hypogammaglobulinemia due...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatrics international 2022-01, Vol.64 (1), p.e15362-n/a
Hauptverfasser:	Imai, Kohsuke, Ishii, Tomonori, Nonoyama, Shigeaki, Yasumi, Takahiro, Kanegane, Hirokazu, Fukushima, Taku, Matsumaru, Masayuki, Akasaki, Tetsushi, Usui, Hideo
Format:	Artikel
Sprache:	eng
Schlagworte:	Agammaglobulinemia Agammaglobulinemia - drug therapy Humans Hypogammaglobulinemia Immunodeficiency Immunoglobulins Immunoglobulins, Intravenous - therapeutic use Immunologic Deficiency Syndromes - drug therapy Injections, Subcutaneous Japan Original Patients Pediatrics postmarketing product surveillance Primary immunodeficiencies Safety subcutaneous injections
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!